Mohit Garg

Managing Director

Despite having a horrendous impact on the business landscape world-over, the recent covid pandemic provided a serious boost to global pharmaceutical in­dustry. In a highly populated country like India, the health­care crisis that ensued further highlighted the importance of pharma R&D, adding further fuel to the already flourishing pharma sector in the country. While the 100 percent FDI for pharma sector nationwide has been the major growth factor for this, the increasing prevalence of chronic and lifestyle diseases across the country has resulted in both govern­ment and private sector organizations making significant investments in pharma research, especially with a focus on accelerating the drug discovery & development process. As a result, the demand for quality APIs and pharma intermedi­ates is at all-time high lately.

As per Mordor Intelligence’s recent report, the pharma intermediates market size which currently stands at $42.31 billion is expected to be worth $60.52 billion by 2029, growing at a CAGR of 7.42 percent during the forecast period. While there are currently around 500 API manufacturers across India contributing approximately eight percent of the global API demand, one company that stands-out is Saral Chemtech. Based in Muzaffarnagar (UP), SARAL was established in 2019 with a vision to become a world-class manufacturer of high quality APIs and their intermediates. “Due to lack of demand from the customers during covid, we initially setup the plant only for the production of diclofenac sodium and aceclofenac. But once the scenario improved after a couple of years, we not only added two more products to our production portfolio, but also enhanced our manufacturing capacity to successfully cater to the present demand”, says Mohit Garg, Managing Director, Saral Chemtech.

Expansive Product Portfolio

As one of the fastest growing manufacturer of APIs and intermediates in India today, Saral Chemtech boasts of having one of the broadest range of products. Some of the key APIs that the company manufactures include Aceclofenac IP/BP/EP, Diclofenac Sodium IP/BP/USP, Diclofenac Potassium BP/USP, Mefenamic Acid IP/BP/USP, Nimesulide BP, Ornidazole IP, Fluconazole IP/BP/USP and Guaifenesin IP/BP/USP. Similarly, under intermediates, its product portfolio includes 1-(2,6 Dichlorophenyl)-2-indolinone, 2,6 Dichlorophenol, Mono Methyl Chloroacetate, 2,6 Dichloro Diphenylamine and 2-Phenoxy Aniline.

“Prior to launching a new product into market, we do a thorough market analysis about the current players in the industry, their import-export data and many other critical aspects. Any loophole that is identified in their product or process is then passed on to our in-house R&D team, which is then tasked with developing the same product that is better in terms of quality as well as cost. Today, our APIs and intermediates are not only exported to Brazil, Vietnam, Mexico, Pakistan and Bangladesh, but we are also the first Indian aceclofenac API manufacturer to get approval from the CDE, CHINA to supply the same in their country.

Quality-oriented Manufacturing Process

As a WHO-GMP certified company, Saral Chemtech leaves no stone unturned to ensure the quality of its products. The facility is equipped with all cutting-edge instruments such as High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Fourier Transform Infra-red Spectrophotometer (FTIR), UV-VIS Spectrophotometer, Polarimeter, Karl Fischer Titrator, and many more wet analysis equipment. Additionally, the company also has stringent SOPs in place to make sure that all its products are not only of top-notch quality, but also comply with the latest pharmaceutical regulations.

“We also have a highly skilled quality control & quality assurance team that keeps a strict vigil on every stage of production and even takes care of the necessary documentation and approval processes across various countries. Presized, validated and systematic analytical practices give us more accurate results to control the quality in a systematic manner. Also, our state-of-the-art R&D center with the latest laboratory rotary reactors are capable of carrying-out various types of reactions such as Freidle Craft, Chlorination, Methylation, Carbolixation and many more. As a result, we are able to deliver high valuable molecules in small scales as well”, adds Mohit.

With such industry-best practices, SARAL has grown significantly within just years of its inception and is today renowned as the second largest producer of aceclofenac in Asia. Some of the major pharmaceuticals that it is currently catering to include Mankind Pharma Ltd, Alkem Laboratories Ltd, Intas Pharmaceuticals Ltd, Pinnacle Life Science Pvt Ltd, Akums Drugs & Pharmaceuticals Ltd., and many more. Further, the company is also in the process of getting the audit done and procuring approvals to supply for few more multinational pharmaceuticals such as Cadila Pharmaceuticals Ltd and Ajanta Pharma Ltd by the end of this year.

Mr Mohit Garg has achieved all these goal under the guidance of his father Shri Raghuraj Garg Ji who is prominent industrialist in his region having a rich experience of more than 30 years and of course a collective team work of across all the departments of the company. Going ahead, SARAL is also going to plan to setup another manufacturing facility near by this area for adding more products in our portfolio. We are in discussion with UP Government to lease a land in pharma API Park developing by UP Government.